UC-Davis

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
2	Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	Ongoing, but not recruiting	Closed	Sorafenib (Nexavar, BAY 43-9006)	NCT00265798
2	MEK Inhibitor AZD6244 With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	Ongoing, but not recruiting	Closed	AZD6244 plus Temsirolimus	NCT01206140